sRAGE: potential therapeutic target for Alzheimer’s disease

S. Danning Zhu

doi:10.1117/12.2669633

24 March 2023 sRAGE: potential therapeutic target for Alzheimer’s disease

S. Danning Zhu

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126114K (2023) https://doi.org/10.1117/12.2669633
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Every 4 seconds, someone is diagnosed with Alzheimer's disease (AD). It’s the most common cause of dementia, affecting over 40 million people worldwide. In 2016, there are about 40 million people suffering from AD around the world, and the number may double every 20 years. Depending on the stages of disease, symptoms include memory lost, abnormal behaviors and spirits as well as inability to communicate. The specific pathogenesis of AD is not very clear at present, but there are many mechanisms explored, such as abnormal accumulation of amyloid-β in the brain, tau protein hyperphosphorylation, inflammatory injury. Currently, almost all the R&D pipelines of major companies around the world focus on the theoretical basis of the above mechanisms to develop drugs that can reverse these processes. The clinical failure rate of drugs for AD is as high as 97.3%, which consumed a lot of time and money of involved families. Thus, scientists and pharmaceutical companies have been committed to developing more effective drugs. In this review, we introduce a protein called sRAGE as a novel approach that can be used to control AD based on current mechanisms. sRAGE acts as decoy receptor of RAGE which is involved in multiple mechanisms of AD, preventing RAGE from binding to its ligands. Therefore sRAGE can control AD by reducing RAGE-mediate Aβ transportation into brain and activation of microglia and NF-κB.

Citation Download Citation

S. Danning Zhu "sRAGE: potential therapeutic target for Alzheimer’s disease", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126114K (24 March 2023); https://doi.org/10.1117/12.2669633

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available